Redeye updates its estimates and valuation following Serstech's Q4 2024 report.
Solwers had already released a profit warning for Q4 2024 and the full year on 1 February.
Redeye updates on W5 following its Q4-results where topline was as expected while profitability was ...
Redeye comments on WntResearch’s Q4 2024 report. The report was undramatic, which was expected in ou...
Tangiamo Touch Technology (”Tangiamo” eller ”Bolaget”) publicerade den 27 februari 2025 Bolagets del...
Addlife ökade omsättningen med 11% under fjärde kvartalet 2024, organisk tillväxt exklusive valutapå...
Redeye provides a research update on Faron Pharmaceuticals following the company’s recent H2 report.
Redeye comments on CLS’s directed issue, raising up to SEK37m.
Q4e: revenues of DKK 341m, EBIT of DKK 19m, 6% margin At least two good reasons for earnings growth ...
IPU ramp-up delayed: we cut '25e-'26e revenue by 44-33% UPF partnerships opens a large new segment T...
Analyst Group initiates equity research coverage on Genetic Analysis AS (“Genetic Analysis” or the “...
Voi, som är VNV Globals näst största innehav, kom med en stark Q4-rapport.
Redeye provides a short comment on Ortoma’s Q4 report this morning.
Redeye provides an initial comment on the Q4 2024 report from Serstech.
Redeye comments on Verve Group’s Q4 2024 results, which came in stronger than expected across the bo...
Redeye comments on W5 Solutions Q4-results where sales were in line with expectations while EBITDA w...
First Venture Sweden (”First Venture” eller ”Bolaget”) är ett investmentbolag med fokus på snabbväxa...
Redeye provides a research update following the Q4 report published by Lipum earlier today.
- Adj. EBIT 31% vs cons, 51% vs ABG - Order backlog +10% y-o-y, slightly weaker than expected - We e...
Hifab Group AB (”Hifab”, ”Koncernen” eller ”Bolaget”) är en konsultgrupp inom samhällsbyggnad, vilka...